Minerva Neurosciences, Inc.
NERV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NERV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) diseases, with its lead candidate roluperidone in Phase 3 trials for negative symptoms in schizophrenia.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$231.1M
Cash Runway
16.7 moLead Asset
roluperidone (Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2028Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials · 1 catalyst for Minerva Neurosciences, Inc..
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) diseases, with its lead candidate roluperidone in Phase 3 trials for negative symptoms in schizophrenia.
- Lead candidate roluperidone is in a Phase 3 trial for negative symptoms in schizophrenia [sec · filed 2026-05-27].
- As of June 30, 2026, cash & equivalents were $24.8M, with net income of $17.5M and shareholders' equity of -$32.1M [sec].
- Accumulated deficit was approximately $796.7 million as of June 30, 2026 [sec_mda · as of 2026-08-07].
- No products approved for commercial sale and no revenue from product sales to date [sec_mda · as of 2026-08-07].
- Management believes existing cash will fund operations for at least 12 months from the date of the June 30, 2026 financial statements [sec_mda · as of 2026-08-07].
What works
- Roluperidone is in a Phase 3 trial targeting negative symptoms in schizophrenia, a high unmet medical need [sec · filed 2026-05-27].
- Cash position of $24.8M as of June 30, 2026, provides near-term operational runway [sec].
- Net income of $17.5M in the latest reported period may indicate improved financial management or one-time gains [sec].
What to weigh
- Accumulated deficit of $796.7M as of June 30, 2026, reflects a long history of losses [sec_mda · as of 2026-08-07].
- No approved products or product revenue, and the company may never achieve profitability [sec_mda · as of 2026-08-07].
- Shareholders' equity is negative (-$32.1M as of June 30, 2026), indicating a weak balance sheet [sec].
- The company will require additional capital to finance operations, which may not be available on acceptable terms [sec_mda · as of 2025-05-13].
From the filings
Quoted directly from source documents.
Roluperidone is in Phase 3 for negative symptoms in schizophrenia.
“for the treatment of negative symptoms in schizophrenia.”
SEC filings · May 27, 2026
Accumulated deficit as of June 30, 2026.
“had an accumulated deficit of approximately $796.7 million.”
SEC MD&A · August 7, 2026
No product revenue to date.
“We have no products approved for commercial sale and have not generated any revenue from product sales to date”
SEC MD&A · August 7, 2026
Cash runway of at least 12 months from June 30, 2026.
“we believe will be sufficient to meet our operating commitments for the next 12 months from the date our interim condensed financial statements are issued.”
SEC MD&A · August 7, 2026
Catalyst timeline
- 2028-12-01 · Phase3_Topline — Topline results from a 12-week, randomized, double-blind, placebo-controlled monotherapy study of roluperidone for negative symptoms in schizophrenia.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Phase 3 trial of roluperidone may fail to meet endpoints, delaying or ending development [sec · filed 2026-05-27].
- Need for additional financing — Company will require additional capital; may not be available on acceptable terms [sec_mda · as of 2025-05-13].
- No approved products or revenue — No products approved for commercial sale and no product revenue to date [sec_mda · as of 2026-08-07].
- Regulatory and FDA feedback risks — Interactions with FDA may affect trial design, timeline, or approval [sec · filed 2026-05-27].
What to watch
- Phase 3 topline data for roluperidone expected December 1, 2028 [catalyst].
- Cash runway and any additional financing activities [sec_mda · as of 2026-08-07].
- FDA feedback on the confirmatory trial design for roluperidone [sec · filed 2026-05-27].
- Progress toward potential commercialization and revenue generation [sec_mda · as of 2026-08-07].
Sources: SEC filings · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Minerva Neurosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Minerva Neurosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
16.7 months
OCF -$13M · Net income $17M
Lead: Phase 3
1 candidate
1 upcoming, next in ~824d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$190.4M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 8,588,518 | $51.7M |
| federated hermes, inc. | 5,113,224 | $30.8M |
| balyasny asset management l.p. | 4,258,600 | $25.7M |
| vanguard capital management llc | 3,691,662 | $22.2M |
| farallon capital management llc | 2,365,000 | $14.2M |
| trails edge capital partners, lp | 1,419,000 | $8.5M |
| adage capital partners gp, l.l.c. | 1,419,000 | $8.5M |
| dv trading llc | 889,254 | $5.4M |
| acuta capital partners, llc | 709,500 | $4.3M |
| millennium management llc | 708,291 | $4.3M |
Showing top 10 of 39 institutional holders of Minerva Neurosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 2.8%
- Days to cover
- 2.9
- Shares short
- 1,156,257
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NERV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Minerva Neurosciences, Inc.?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) diseases, with its lead candidate roluperidone in Phase 3 trials for negative symptoms in schizophrenia.
What is Minerva Neurosciences, Inc.'s lead drug candidate?
Minerva Neurosciences, Inc.'s most advanced tracked candidate is roluperidone (Phase 3) for Negative Symptoms of Schizophrenia.
What is Minerva Neurosciences, Inc.'s next catalyst?
Minerva Neurosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate " — expected December 1, 2028.
Who is the CEO of Minerva Neurosciences, Inc.?
Dr. Remy Luthringer Ph.D. is the chief executive officer of Minerva Neurosciences, Inc. (NERV).
Where is Minerva Neurosciences, Inc. headquartered?
Minerva Neurosciences, Inc. (NERV) is headquartered in Burlington, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.